AAAAAA

   
Results: 1-16 |
Results: 16
Re: Dose proportionality of fluticasone propionate hydrofluoroalkane pressurized metered dose inhalers (pMDIS) and comparability with chlorofluorocarbon pMDIS [Respir Med 2000; 94 (Suppl. B): S10-S16] - Response
Authors: Daley-Yates, PT Kunka, RL
Citation: Pt. Daley-yates et Rl. Kunka, Re: Dose proportionality of fluticasone propionate hydrofluoroalkane pressurized metered dose inhalers (pMDIS) and comparability with chlorofluorocarbon pMDIS [Respir Med 2000; 94 (Suppl. B): S10-S16] - Response, RESP MED, 95(2), 2001, pp. 161-163
Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology
Authors: Derendorf, H Daley-Yates, PT Pierre, LN Efthimiou, J
Citation: H. Derendorf et al., Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology, EUR RESP J, 17(1), 2001, pp. 157-158
Systemic bioavailability of fluticasone proprionate - Reply
Authors: Daley-Yates, PT
Citation: Pt. Daley-yates, Systemic bioavailability of fluticasone proprionate - Reply, BR J CL PH, 52(4), 2001, pp. 458-460
Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man
Authors: Daley-Yates, PT Price, AC Sisson, JR Pereira, A Dallow, N
Citation: Pt. Daley-yates et al., Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man, BR J CL PH, 51(5), 2001, pp. 400-409
Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations
Authors: Daley-Yates, PT Baker, RC
Citation: Pt. Daley-yates et Rc. Baker, Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations, BR J CL PH, 51(1), 2001, pp. 103-105
A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate
Authors: Crim, C Pierre, LN Daley-Yates, PT
Citation: C. Crim et al., A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate, CLIN THER, 23(9), 2001, pp. 1339-1354
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus((R)) or Turbohaler((R)) dry-powder inhalers to healthy subjects
Authors: Mollmann, H Wagner, M Krishnaswami, S Dimova, H Tang, Y Falcoz, C Daley-Yates, PT Krieg, M Stockmann, R Barth, J Lawlor, C Mollmann, AC Derendorf, H Hochhaus, G
Citation: H. Mollmann et al., Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus((R)) or Turbohaler((R)) dry-powder inhalers to healthy subjects, J CLIN PHAR, 41(12), 2001, pp. 1329-1338
Dose proportionality of fluticasone propionate from hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs
Authors: Kunka, R Andrews, S Pimazzoni, M Callejas, S Ziviani, L Squassante, L Daley-Yates, PT
Citation: R. Kunka et al., Dose proportionality of fluticasone propionate from hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs, RESP MED, 94, 2000, pp. S10-S16
Bioavailability of orally administered micronised fluticasone propionate
Authors: Falcoz, C Oliver, R McDowall, JE Ventresca, P Bye, A Daley-Yates, PT
Citation: C. Falcoz et al., Bioavailability of orally administered micronised fluticasone propionate, CLIN PHARMA, 39, 2000, pp. 9-15
Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant
Authors: Mackie, AE McDowall, JE Ventresca, P Bye, A Falcoz, C Daley-Yates, PT
Citation: Ae. Mackie et al., Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant, CLIN PHARMA, 39, 2000, pp. 17-22
Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler (R) and Diskus (R) powder devices in healthy volunteers
Authors: Mackie, AE McDowall, JE Falcoz, C Ventresca, P Bye, A Daley-Yates, PT
Citation: Ae. Mackie et al., Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler (R) and Diskus (R) powder devices in healthy volunteers, CLIN PHARMA, 39, 2000, pp. 23-30
Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler (R) and Diskus (R) powder devices in patients with mild-to-moderate asthma
Authors: Falcoz, C Horton, J Mackie, AE Harding, SM Daley-Yates, PT
Citation: C. Falcoz et al., Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler (R) and Diskus (R) powder devices in patients with mild-to-moderate asthma, CLIN PHARMA, 39, 2000, pp. 31-37
Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma
Authors: Daley-Yates, PT Tournant, J Kunka, RL
Citation: Pt. Daley-yates et al., Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma, CLIN PHARMA, 39, 2000, pp. 39-45
Fluticasone propionate bioavailability in asthma - Reply
Authors: Woodcock, A Daley-Yates, PT
Citation: A. Woodcock et Pt. Daley-yates, Fluticasone propionate bioavailability in asthma - Reply, LANCET, 356(9242), 2000, pp. 1682-1682
Comparison of pharmacokinetics and systemic effects of inhaled fluticasonepropionate in patients with asthma and healthy volunteers: a randomised crossover study
Authors: Brutsche, MH Brutsche, IC Munavvar, M Langley, SJ Masterson, CM Daley-Yates, PT Brown, R Custovic, A Woodcock, A
Citation: Mh. Brutsche et al., Comparison of pharmacokinetics and systemic effects of inhaled fluticasonepropionate in patients with asthma and healthy volunteers: a randomised crossover study, LANCET, 356(9229), 2000, pp. 556-561
Cushing's syndrome and severe adrenal suppression in patients treated withritonavir and inhaled nasal fluticasone
Authors: Chen, F Kearney, T Robinson, S Daley-Yates, PT Waldron, S Churchill, DR
Citation: F. Chen et al., Cushing's syndrome and severe adrenal suppression in patients treated withritonavir and inhaled nasal fluticasone, SEX TRANS I, 75(4), 1999, pp. 274-274
Risultati: 1-16 |